Abstract A number of factors have been shown to there is a need for intravenous iron, in particular when the patient has absolute or functional iron deficiency, limit the response to recombinant human erythropoietin (r-HuEPO). One major factor appears to be an is intolerant of oral iron, or is not complying well with the oral regimen. inadequate iron supply to the bone marrow. Erythropoiesis is dependent upon a continuous supply
'absolute iron deficiency' caused by depletion of iron Introduction stores. At present there are three main parameters available to clinicians wishing to monitor iron status Since the introduction of recombinant human erythroin their patients: serum ferritin and transferrin satura-poietin (r-HuEPO) it has become apparent that tion ( TFS ), which are indirect measurements, and the adequate iron supply to the bone marrow is essential percentage of hypochromic red cells, which directly for a satisfactory haematopoietic response. This is reflects marrow iron status. Ferritin levels should be particularly important because large quantities of measured before starting r-HuEPO therapy to ensure r-HuEPO may be wasted, which impacts on the costadequate iron stores (>200 mg/l ), and when patients effectiveness of this treatment. Based on the literature, move from the correction phase to the maintenance 80-90% of dialysis patients on r-HuEPO will require phase of therapy (have stores become depleted during iron at some stage in their therapy. The majority of the correction phase?). In addition, ferritin levels can haemodialysis patients is treated with intravenous iron, give an indication of iron overload following excess while most continuous ambulatory peritoneal dialysis parenteral iron administration. The TFS represents a (CAPD) and pre-dialysis patients are treated with oral balance between iron supply by stores and demand by iron, because of lower iron needs and the practicality bone marrow. A saturation below 20% probably indi-of achieving intravenous access. cates iron-deficient erythropoiesis. However, this is an indirect measure of marrow iron supply and wide fluctuations have been observed when determined at Monitoring iron stores different time points. The percentage of hypochromic red blood cells is measured by flow cytometry and a Serum ferritin hypochromic subpopulation of more than 10% (normal Serum ferritin (S-ferritin) provides a measurement of percentage <2.5%) indicates iron-deficient erythrostorage iron. Normal values are 20-100 mg/l in females poiesis. However, not all departments may have access and 30-300 mg/l in males. Approximately 100 mg/l to the required equipment. The aim of iron S-ferritin represents 1 g of storage iron [1]. The minsupplementation is to provide sufficient iron for the imal S-ferritin required in uraemic patients for response correction phase and to replace iron losses to r-HuEPO is above 200 mg/l according to Allegra (1500-2000 mg/year in haemodialysis patients) during et al. [2] . In patients on intravenous iron, S-ferritin the maintenance phase of r-HuEPO therapy. This should be determined several times per year as a amounts to a daily iron need in the range of 5-7 mg, measure of iron stores, in order to exclude iron overwhich is well above the normal dietary intake and load. One has to bear in mind, however, that S-ferritin absorptive capacity of the human intestine. Therefore, will be elevated during parenteral iron therapy. For this reason, it is advisable to determine S-ferritin 3-6 therapy, one should be cautious not to raise S-ferritin cytes, averaging 26 pg/cell in healthy individuals. above 500 mg/l (equivalent to 5 g of storage iron), Recently, Fishbane et al. [10] showed that dialysis because above this threshold iron is being stored patients have normal CHr values (27.5±2.8 pg/cell ). progressively outside the reticulo-endothelial system. Values below 26 pg were highly predictive of ironIn fact there are a number of reports in the literature deficient erythropoiesis. Within 48 h after the intravethat describe abnormalities in granulocyte function, nous administration of 1000 mg of iron dextran, the such as impaired phagocytosis and intracellular killing majority of these patients responded with an increment in iron overloaded dialysis patients [3,4], leading to an in their CHr values. If these findings can be corroboincreased incidence of bacterial infections [5] . rated by other authors, this parameter may turn out to be a helpful tool to diagnose iron-deficient Transferrin saturation erythropoiesis.
The transferrin saturation ( TFS) is a measure of the RBC zinc protoporphyrin iron content of transferrin, the only protein in the plasma that transports iron from the stores to the bone When iron availability is reduced during haem synmarrow. One has to bear in mind, however, that the thesis, zinc instead of iron is incorporated into the TFS provides no information on iron stores or utiliza-protoporphyrin molecule. During adequate iron availtion of iron by the bone marrow. Values below 20% ability, zinc protoporphyrin ( ZnPP) concentrations in are considered to be associated with suboptimal deliv-RBCs are below 40 mmol/mol haem. Values above ery of iron to the marrow, in particular during pharma-90 mmol/mol haem are considered to indicate ironcological stimulation of erythropoiesis by r-HuEPO. deficient erythropoiesis (or lead intoxication). As with Values below 20% may even be seen in the presence of hypochromic RBC populations and CHr, ZnPP repnormal or high S-ferritin values, indicating functional resents a direct measure of iron availability to the iron deficiency [6 ] . Functional iron deficiency may marrow. A major difference, however, is that ZnPP is occur during high-dose r-HuEPO therapy or in the determined in the whole RBC population of the represence of an acute phase reaction. Recent recom-spective sample, rather than a subpopulation. Based on mendations regarding iron supplementation suggest the relatively long life span of RBCs in the circulatreating functional iron deficiency with intravenous tion, ZnPP integrates information on iron availability iron in those cases where an acute bacterial infection over a prolonged period of time (similar to HbA 1c in can be excluded [7] . diabetes mellitus). In the clinical setting, Hastka et al. [11] showed that ZnPP values above 100 mmol/mol Percentage of hypochromic red blood cells haem correctly identified iron-deficient erythropoiesis in nine out of 10 dialysis patients on r-HuEPO, as Hypochromia is defined as an individual red cell haemeasured by their response to intravenous iron. On moglobin concentration below 28 g/dl and is measured the other hand, Braun et al. [12] were not able to by flow cytometry. A hypochromic red blood cell corroborate these findings. What is more, there is a (RBC ) subpopulation of less than 2.5% is considered significant number of patients displaying ZnPP values normal, while values above 10% indicate iron-deficient between 50 and 100 mmol/mol haem, who may or may erythropoiesis [8] . Long-standing iron-deficient erythnot respond to intravenous iron [13] . In summary, the ropoiesis during r-HuEPO therapy may result in measurement of ZnPP seems to provide less timely hypochromic RBC subpopulations of more than 50% information of iron availability to the bone marrow as [9] . Hypochromic RBCs are highly sensitive for compared with hypochromic RBCs. Its use may be detecting iron-deficient erythropoiesis, but this paramrecommended when the other parameters are not eter can only be obtained by using certain types of available. haematology analysers ( Technikon H1-, H2-or H3-Systems; Bayer Diagnostics, Munich, Germany), which are able to determine the haemoglobin concen-Iron therapy tration in individual RBCs.
It has to be emphasized, however, that uraemic Need of iron in haemodialysis patients patients not on r-HuEPO may have a normal percentage of hypochromic RBCs despite reduced iron stores The aim of iron therapy is to provide sufficient iron and/or low transferrin saturations, due to their hypo-for both the correction and maintenance phases of generative type of anaemia. Once r-HuEPO therapy is r-HuEPO therapy. The fact that it will take 150 mg of started and erythropoiesis is stimulated, huge numbers iron to synthesize 1 g of haemoglobin can be used of hypochromic RBCs will be released within a few to approximate the amount of iron necessary for days into the circulation [9] . Thus, this parameter is a haem synthesis during the correction phase. Once the direct measure of the relationship between iron avail-target haematocrit is reached, the aim of iron ability to, and iron demand of, the bone marrow. supplementation is to substitute for losses during extracorporeal therapy, which may amount to up to 2 g of Reticulocyte haemoglobin content iron per year [14] . For most patients, such quantities of iron can only be administered parenterally, because Using the H3-System, the reticulocyte haemoglobin content (CHr) can be determined in individual reticulo-oral iron, particularly in higher doses, is accompanied Iron monitoring and supplementation 11 by significant intestinal side effects in most individuals. doses, such as 100 mg [18] 20] . The major long-term risk associated with intravenous iron is iron overload, which may easily be prevented by monitoring S-ferritin values.
Efficacy of intravenous iron preparations
While iron dextran can be given in relatively high Need of iron in pre-dialysis and CAPD patients single doses, there is a delay before iron is available to the bone marrow. This is due to processing in the Both pre-dialysis and CAPD patients frequently have reticuloendothelial system, which is necessary to liberhigher baseline haemoglobin levels compared with ate iron from the complex. Thus, Macdougall et al. haemodialysis patients and the loss of iron is much [21] found that ferritin did not rise until 4-7 days after less pronounced. Therefore, the need for iron is lower administration of iron dextran, while after injection of in these two groups of patients, during both the iron saccharate, ferritin levels had already increased correction and maintenance phases. It is for these after 24-48 h. reasons, together with the practicality of gaining venous access, that many nephrologists start these patients on a course of oral iron. Only those who do Conclusion not tolerate this form of therapy, or who cannot be supplemented adequately, are then switched to intraAbsolute and functional iron deficiency are probably venous iron. In such patients, iron dextran and iron the most frequent causes of r-HuEPO resistance. The saccharate should preferably be used, as both comdiagnostic evaluation of iron status includes S-ferritin pounds can be given safely in higher doses (fewer levels, TFS and percentage of hypochromic RBCs injections necessary). Furthermore, due to their rela-(when available). The combination of these three tively high molecular weight, they are not filtered by parameters allows for exact characterization of iron the glomerulus and thereby cannot exert any potential metabolism in the majority of patients with renal tubulotoxic side effects.
failure. S-ferritin values below 200 mg/l suggest absolute iron deficiency, while in functional iron deficiency
Iron preparations
there is a low TFS (<20%) and an increased percentage of hypochromic RBCs (>10%). Adequate iron therapy in iron-depleted haemoSafety of intravenous iron preparations dialysis patients may result in a considerable reducIn continental Europe there are presently two different tion of the r-HuEPO dose. Intravenous iron iron preparations available: iron-(III )-gluconate and supplementation is recommended in haemodialysis iron-(III )-hydroxysaccharate, while in the UK both patients during both the correction and maintenance iron hydroxysaccharate and iron dextran are available, phases of r-HuEPO treatment. In most countries, the and in North America iron dextran is almost exclu-choice of iron complex will depend on the iron preparasively used. In terms of safety, two major aspects must tion available. In pre-dialysis and CAPD patients be considered. 1) With the administration of iron (without absolute iron deficiency), oral iron therapy dextran there is a distinct possibility of anaphylactic may be feasible, as renal anaemia is frequently less reactions due to preformed antibodies to dextran. severe and the loss of iron less pronounced compared According to Hamstra et al. clinical setting most centres prefer to inject lower single
